Vaginal Atrophy (Atrophic Vaginitis) Pipeline Review, H1 2015 - 8 Companies & 8 Drug Profiles
M2 - Thu Jun 25, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brrxqg/vaginal_atrophy) has announced the addition of the "Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actavis plc - EndoCeutics, Inc. - Foamix Pharmaceuticals Ltd. - MediGene AG - Pantarhei Bioscience BV - Peptonic medical AB - RestorGenex Corporation - TherapeuticsMD Inc. Drug Profiles - esterol - estradiol hemihydrate - oxytocin - prasterone - RES-102 - sinecatechins - TX-004HR - WC-3011 For more information visit http://www.researchandmarkets.com/research/br...al_atrophy
TXMD: 7.96 (+0.09), FOMX: 11.18 (+0.22)
Genital Warts (Condylomata Acuminata) Pipeline Review 2015 - 12 Companies & 14 Drug Profiles
M2 - Wed Jun 24, 10:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tcqv8c/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Agilvax, Inc. - Anaconda Pharma - Biogenomics Limited - BioMAS Ltd. - Foamix Pharmaceuticals Ltd. - G&E Herbal Biotechnology Co., Ltd. - Helix BioPharma Corp. - LEO Pharma A/S - MediGene AG - NanoViricides, Inc. - Novan, Inc. - Tamir Biotechnology, Inc. Drug Profiles - AP-611074 - AS-101 - AX-03 - HerpeCide-I - human papilloma virus [strains 6,11] (bivalent) vaccine - imiquimod - ingenol mebutate - interferon alfa-2b (recombinant) - interferon alpha-2b (recombinant) - PP-210 - ranpirnase - SB-206 - sinecatechins - SRT-100 For more information visit http://www.researchandmarkets.com/research/tc...ital_warts
FOMX: 11.18 (+0.22), NNVC: 1.56 (-0.04)
T-Cell Leukemia Pipeline Review, H1 2015 - 14 Companies & 20 Drug Profiles
M2 - Thu Jun 11, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2b68lm/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - iDD biotech SAS - Kyowa Hakko Kirin Co., Ltd. - MediGene AG - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Pharmacyclics, Inc. - Sanofi - Stemline Therapeutics, Inc. - Theravectys S.A. - Tolero Pharmaceuticals, Inc. Drug Profiles - AGS-67E - alemtuzumab - Antibody to Inhibit HLA-A2 for Neurology, Infectious Diseases and T-Cell Leukemia - BMS-906024 - Cell Therapy to Target CD38 for cancer - IDD-003 - INA-01 - lenalidomide - MMIG-202 - mogamulizumab - Monoclonal Antibodies to Antagonize TCR for Leukemia and Autoimmune Disease - Monoclonal Antibody to Target CCR9 for T Lymphoblastic Leukemia - NK-314 - Oncolytic Virus to Target Glycoprotein gp160 for T-cell Leukemia - PCI-34051 - PF-03084014 - SL-101 - Synthetic Peptide for Oncology and Male health - THV-02 - TP-0903 For more information visit http://www.researchandmarkets.com/research/2b...l_leukemia
PCYC: 261.25 (+1.70), PFE: 34.36 (+0.50), BMY: 69.27 (+1.38), STML: 11.86 (+0.03), CELGZ: 2.15 (+0.14)
Global Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics Development Pipeline Review, H1 2015 - 16 Drug Profiles & 11 Companies
M2 - Fri Jun 05, 8:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wnpg9f/basal_cell) has announced the addition of the "Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - Biofrontera AG - Biogenomics Limited - Biosceptre International Limited - Bristol-Myers Squibb Company - Genextra S.p.a. - MediGene AG - Novartis AG - Oncovir, Inc. - Redx Pharma Ltd - Transgene SA Drug Profiles - aminolevulinic acid hydrochloride - BIL-010t - BMS-833923 - CIGB-128 - CS-S/BCC-1 - CS-TATI-1 - DAC-060 - erismodegib - interferon alfa-2b (recombinant) - LEQ-506 - Oshadi D Oshadi R - Poly-ICLC - sinecatechins - Small Molecule to Inhibit Smoothened Receptor for Basal Cell Carcinoma - Small Molecules to Inhibit Casein Kinase 1 for Cancer - TG-1042 For more information visit http://www.researchandmarkets.com/research/wnpg9f/basal_cell
BMY: 69.27 (+1.38), NVS: 103.22 (+3.20)
Seeking Alpha's Biotech Weekly: Biogen's Plaque Attack, Amgen Or Gilead?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
TRVN: 6.51 (+0.61), MDT: 74.37 (+1.28), CLDX: 24.89 (+0.42), FOMX: 11.18 (+0.22), AMGN: 154.10 (+2.79), AET: 114.60 (+1.93), NKTR: 11.40 (+0.22), CELG: 118.84 (+1.97), HUM: 187.25 (+1.09), CANF: 2.00 (+0.09), ANTM: 159.73 (+1.15), NVO: 57.68 (+2.91), GILD: 113.74 (+0.38), GERN: 4.22 (+0.13), AZN: 66.45 (+1.90), CLLS: 35.72 (+1.27), WCG: 87.93 (+1.54), FOLD: 14.48 (+0.44), REGN: 526.01 (+16.98), CUR: 1.69 (-0.01)
Medigene AG: Addressing The CAR-T Market Pain Points
Decision Analytics - Seeking Alpha - Wed Mar 18, 11:51AM CDT
I have written about the market opportunity for adoptive cancer immunotherapy before when my interest was piqued by the incredible appreciation of a number of early-stage CAR-T therapy companies (a form of adoptive immunotherapy). Companies such as...
MDVN: 106.81 (-2.19), JNJ: 99.53 (+1.13), ZIOP: 11.17 (+0.69), BLCM: 19.58 (+0.74), KITE: 64.36 (+1.05), JUNO: 52.05 (+1.72), NVS: 103.22 (+3.20)
Primary Biliary Cirrhosis Therapeutics Pipeline Review 2015 - 9 Companies & 10 Drug Profiles
M2 - Tue Mar 03, 6:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/h7976j/primary_biliary) has announced the addition of the "Primary Biliary Cirrhosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Primary Biliary Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Biliary Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Dr. Falk Pharma GmbH - GlaxoSmithKline plc - Intercept Pharmaceuticals, Inc. - Johnson & Johnson - MediGene AG - NGM Biopharmaceuticals, Inc. - Shire Plc - Virobay Inc. Drug Profiles - A-4250 - budesonide - FFP-104 - GSK-2330672 - NGM-282 - obeticholic acid - RhuDex - SHP-625 - ustekinumab - VBY-825 For more information visit http://www.researchandmarkets.com/research/h7...ry_biliary
JNJ: 99.53 (+1.13), SHPG: 250.34 (+7.35), ICPT: 247.71 (+4.45), VBAY: (), GSK: 42.45 (+0.65)
Biliary Cirrhosis Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Mon Jan 05, 1:30PM CST
The report "Biliary Cirrhosis - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Biliary Cirrhosis. Primary biliary cirrhosis is a long-term liver disease in which the bile ducts in the liver become damaged. It is most likely an autoimmune disease, where the body's immune system attacks its own cells. It generally strikes women between the ages of 40 and 60. Symptoms of Primary biliary cirrhosis include the following Fatigue, Pruritus, Right upper quadrant discomfort, Hepatomegaly, Hyperpigmentation, Splenomegaly, Jaundice, Xanthelasmata, Sicca syndrome and Kayser-Fleischer rings. Treatment for primary biliary cirrhosis is difficult, because the immune system appears to be involved. Complete Report is Available @ http://www.reportsnreports.com/reports/322822...-2014.html
JNJ: 99.53 (+1.13), SHPG: 250.34 (+7.35), ICPT: 247.71 (+4.45), VBAY: (), GSK: 42.45 (+0.65)
Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 12.08 (+0.43), INO: 7.46 (+0.19), ADXS: 18.58 (+0.34), GSK: 42.45 (+0.65), NKTR: 11.40 (+0.22), NVS: 103.22 (+3.20)
T-Cell Leukemia Therapeutics Pipeline Review 2014 - 15 Drug Profiles from 10 Leading Pharma Companies
M2 - Wed Sep 10, 10:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shcdvv/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Kyowa Hakko Kirin Co., Ltd. - Sanofi - MediGene AG - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Celgene Corporation - Pharmacyclics, Inc. - Stemline Therapeutics, Inc. - Applied Immune Technologies Ltd Drug Profiles - alemtuzumab - mogamulizumab - lenalidomide - PF-03084014 - BMS-906024 - PCI-34051 - NK-314 - Recombinant Protein for CNS, Oncology, Hematological Disorders and Metabolic Disorders - Anti-TCR Monoclonal Antibodies for Leukemia and Autoimmune Disease - MMIG-202 - INA-01 - SL-101 - Antibody Targeting HLA-A2 for Neurology, Infectious Diseases and Oncology - Synthetic Peptide for Oncology and Male health - Cell Therapy to Target CD38 for cancer For more information visit http://www.researchandmarkets.com/research/sh...l_leukemia
PCYC: 261.25 (+1.70), PFE: 34.36 (+0.50), BMY: 69.27 (+1.38), STML: 11.86 (+0.03), CELGZ: 2.15 (+0.14)